Wanda Health Secures Funding to Enhance Virtual Care
Wanda Health, an innovative company based in Bristol, UK, is making significant strides in the realm of healthcare technology. Recently, the firm successfully raised £1 million in funding, a milestone that reflects both the burgeoning interest in remote patient monitoring and the efficacy of their virtual care platform. The funding round was led by EMV Capital Partners Limited, highlighting the investment community's confidence in Wanda Health's potential. Following this funding round, EMV Capital Partners holds a fully diluted equity stake of 21.9% in Wanda Health, which translates to a post-investment fair value of £1.35 million. Notably, this valuation represents an impressive 21.5 times increase from their initial investment of £62,000, which was provided through in-kind services just a few months prior in May 2024.
The funds raised will be strategically utilized to enhance Wanda Health’s capabilities, particularly in the development of disease-specific artificial intelligence algorithms aimed at assessing readmission risks.
In addition to improving their technological framework, the company plans to expand its footprint in the U.S. market by focusing on both ‘Fee for Service’ and ‘Value Based Care’ models. This dual approach not only seeks to bolster Wanda Health’s market presence but also aims to create new revenue streams for its partner network across various market segments. Furthermore, the company is determined to navigate the regulatory landscape effectively, working toward obtaining FDA clearance for an outpatient-based predictive cardiovascular risk indicator.
A remarkable aspect of Wanda Health’s operations is its origins; the company is a spinout from UCLA and specializes in offering a comprehensive remote patient monitoring and virtual care platform that caters to both UK and U.S. healthcare markets. Operating as a Software-as-a-Service (SaaS) solution, it employs cloud hosting along with proprietary machine learning and artificial intelligence capabilities. This allows healthcare providers and payers to detect health exacerbations early on, which is crucial for managing both acute and chronic conditions. Recently, Wanda Health forged a partnership with the COPD Foundation, granting them access to clinical experts and guideline content, as well as potential joint marketing opportunities. This collaboration will enhance their platform's capabilities, especially for conditions such as Chronic Obstructive Pulmonary Disease (COPD), which affects a staggering 400 million individuals worldwide. Such initiatives showcase Wanda Health’s commitment to improving patient outcomes while simultaneously reducing healthcare costs.
Click here for a full list of 6,481+ startup investors in the UK